Lymphoma was the first cancer to benefit from chemotherapy over a half century ago. Continuous progress has led to dramatic improvement in the outcome of patients with lymphoma. There has been a clear acceleration in the understanding of the biology of lymphoma, which has led to the development of a number of novel biological agents often called targeted therapies. Such therapies will likely replace chemotherapy in several situations moving forward.

The Lymphoma Division has been at the forefront in the development of many of these novel therapies, particularly in mantle cell lymphoma (all three novel agents approved), diffuse large cell lymphoma, follicular lymphoma, T-cell lymphomas and Hodgkin lymphoma.

Stem cell transplantation, as well as other immunotherapy approaches, particularly the use of checkpoint inhibitors (to unleash the immune system), or genetically modified T-cells (CAR-T cells) will definitely change the future management of lymphoma.

The Lymphoma Division Team

RCCA0131

TATYANA FELDMAN, M.D.
Director, T- Cell Lymphoma Service

READ BIO

RCCA0131

ANDRE GOY, M.D., M.S.
Chairman and Director, Lymphoma Division Chief, Chief Science Officer and Director of Research and Innovation of RCCA, Professor of Medicine, Georgetown University

READ BIO

RCCA0131

LORI ANN LESLIE, M.D.
Hematologist/Oncologist, Lymphoma

READ BIO

RCCA0131

ALAN SKARBNIK, M.D.
Hematologist/Oncologist, Chief of Chronic Lymphocytic Leukemia Program

READ BIO

Pathology

Pritish Bhattacharyya, M.D.
Kar Fai (David) Chow, M.D.
Xiao Yan Yang, M.D.

Advanced Practice Nurse/Clinician

Colleen Bejot
Hoshiquki Iida
Susant Stives
Mary Timberg
Ann McNeil
Beth Boseski
Gabby Maggarelli

 

 

 

Research Nurses

Kara Yannotti
Sabrina Kdiry
Christie Rice
Marisa Valentinetti

Oncology Nurse Navigator

Alex Campaiola
Rebecca Martin
Georgia Rose

Social Work Support Services

Renee Stein Goetz, L.C.S.W.

Call for an appointment

Hackensack: 551-996-5900
Palisades: 201-464-0008

To reach the extensions of Drs. Feldman, Leslie and Goy please dial ext. 3033 and for Dr. Skarbnik, please dial ext. 8297.